Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
NCT07286318Phase 1Recruiting
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nicotinamide in skin cancer, actinic keratosis (AK) and cutaneous squamous cell carcinoma (cSCC) (2 arms). Primary endpoint: Change in baseline actinic keratosis count at 12 months. Started May 2026; status: recruiting.
02
Drugs
nicotinamide
03
Conditions
skin canceractinic keratosis (AK)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT07286318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286318.